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Abstract
Background: Early assessment before the establishment of placental dysfunction has the potential to improve
treatment and prognosis for clinical practice.The objective of the study is to investigate the accuracy of serum
biochemical markers(Pregnancy- Associated Plasma Protein-A (PAPP-A), human Chorionic Gonadotropin (hCG),
Placental Growth Factor (PlGF), Placental Protein 13 (PP13) used in first trimester serum screening in predicting
preelampsia, small for gestational age (SGA) and preterm delivery.
Methods: The data sources included Medline, Embase, Cochrane library, Medion, hand searching of relevant
journals, reference list checking of included articles and contact with experts. Two reviewers independently selected
the articles. Two authors independently extracted data on study characteristics, quality and results.
Results: The results showed low predictive accuracy overall. For preeclampsia, the best predictor was PlGF;
LR + 4.01 (3.74, 4.28), LR-(0.67, 0.64, 0.69). The predictive value of serum markers for early preeclampsia was better
than that of late preeclampsia. For SGA the best predictor was PP13; LR+ 3.70 (3.39, 4.03), LR- 0.70 (0.67, 0.73). For
preterm delivery, the best predictor was PP13; LR+ 4.16 (2.72, 5.61), LR- 0.56 (0.45, 0.67).
Conclusion: First trimester screening analytes have low predictive accuracy for pre-eclampsia, small for gestational age
and preterm delivery. However, the predict value of first trimester analytes is not worse than that of the second
trimester markers.
Background
Preeclampsia, fetal growth restriction (FGR) and preterm
delivery are major contributors to perinatal mortality
and morbidity. They not only alter the immediate out-
comes of pregnancy at the time of delivery but also the
long-term cardiovascular health of the affected women
and children. For example, a history of preeclampsia in-
creases a female’s risk of myocardial infarction, stroke or
diabetes mellitus by two to eight fold over the next two
decades [1]. Moreover, newborns diagnosed with FGR at
birth have a two to eight fold increased risk for hyper-
tension, cardiovascular disease, diabetes mellitus or renal
disease as adults [2, 3].
Recent evidence suggests that the underlying path-
ology of preeclampsia, FGR and preterm delivery takes
place in the first trimester. Earlier assessment before the
establishment of placental dysfunction may have the po-
tential to improve treatment and prognosis for clinical
practice. Numerous stutdies have shown that abnormal
concentration of first trimester serum markers is related
to the onset of preeclampsia, small for gestational age
and preterm delivery. With the increased use of first-
trimester screening for Down syndrome, there is the
opportunity to ‘piggy back’ screening tests for pre-
eclampsia, FGR and preterm delivery onto existing tests.
The purpose of our review was to investigate the
accuracy of serum biochemical markers (Pregnancy-
Associated Plasma Protein-A (PAPP-A), human Chorionic
Gonadotropin (hCG), Placental Growth Factor (PlGF),
Placental Protein 13 (PP13) used in first trimester serum
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screening in predicting preelampsia, small for gestational
age (SGA) and preterm delivery. We systematically reviewed
the available literature and meta-analysed the data.
Methods
Identification of studies
We searched MEDLINE, EMBASE and Cochrane Library
from inception to April 2014 for relevant citations. The
reference lists of all known primary and review articles
were examined to identify cited articles not captured
by electronic searches. The search strategy consisted of
MeSH (medical subject heading) terms, Emtree terms,
and keywords related to the disease (preeclampsia, small
for gestational age, preterm birth, preterm delivery, etc.)
combined with serum markers(PAPP-A, hCG, PP13, PlGF,
etc.). Details of the search strategy are available from the
authors. Language restrictions were not applied. A com-
prehensive database of relevant articles was constructed.
Study selection
The first stage of study selection was the scrutinizing of
the database by two reviewers to identify articles from
title and/or abstract. In a second stage, a search based
on keywords for each of the analytes under review was
performed within the Reference Manager database. The
results of this search were scrutinized by a second
reviewer. In the final stage of study selection the full
papers of identified articles were obtained with final in-
clusion or exclusion decisions made after independent
and duplicate examination of the papers. We included
studies that reported on singleton pregnancies at low
risk in any healthcare setting before the 14th week of
gestation. Test accuracy studies allowing generation of
2 × 2 tables were included.
Data extraction and study quality assessment
Acceptable reference standards for preeclampsia were:
persistent systolic blood pressure ≥ 140 mmHg or diastolic
blood pressure ≥ 90 mmHg with proteinuria ≥ 0.3 g/24 h
or ≥ 1+ dipstick (= 30 mg/dl in a single urine sample),
new after 20 weeks of gestation. Early preeclampsia was
defined as preeclampsia resulting in a delivery before
34 weeks of gestation. Late preeclampsia was defined as
preeclampsia resulting in a delivery after 34 weeks of ges-
tation. Acceptable reference standards for SGA included
birth weight < 10th centile adjusted for gestational age and
based on local population values. We also included severe
SGA defined as birth weight < 5th centile. Preterm delivery
was defined as delivery < 37 weeks. We also included pre-
term delivery < 34 weeks.
All included manuscripts were assessed by at least one
reviewer for study and reporting quality using validated
tools. Items considered important for a good quality paper
were prospective design with consecutive recruitment,
prospective design, adequate description of selection cri-
teria, patient spectrum,test and use of appropriate refer-
ence standard.
Data synthesis and analysis
From the 2 ×2 tables the following were calculated with
their 95 % confidence intervals for individual studies;
sensitivity (true positive rate), specificity (true negative
rate) and the likelihood ratios (LR). Results were pooled
among groups of studies with similar characteristics,
the same threshold and same adverse outcomes. Where
2 × 2 tables contained zero cells, 0.5 was added to each
cell to enable calculations. All statistical analyses were
performed using Stata 11.0 statistical package.
Results
Literature identification and study quality
Figure 1 summarises the process of literature identifica-
tion and selection. There were 1575 primary articles that
met the selection criteria. The initial electronic search
strategy led to screen titles and abstracts of 1406 cita-
tions. Fig. 1 shows the screening and selection process
that was followed for the identification and inclusion of
studies. We retrieved 155 potentially eligible primary
studies for detailed evaluation and inclusion in the sys-
tematic review, and an additional 14 potentially eligible
publications from the reference lists of included studies.
Detailed evaluation led to the exclusion of 66 publica-
tions that did not meet the selection criteria. Overall,
103 studies were considered relevant and were included
in the systematic review. Total number of women in 103
studies is 432,621.
The quality assessment of included studies is summa-
rized in Fig. 2. There was good reporting of prospective
design with consecutive recruitment, prospective design,
adequate description of selection criteria, patient spec-
trum, test and use of appropriate reference standard.
Data analysis
For both analysis for preelampsia, SGA and preterm de-
livery, there was significant heterogeneity in all results.
As a consequence of this the random effects model was
used throughout the study.
Pregnancy associated plasma protein A (PAPP-A)
The results for PAPPA to predict preeclampsia are sum-
marized in Fig. 3. The total number of women in these
studies is 385,643. There were 16 studies for pre-
eclampsia, 10 for early preeclampsia and 3 for late
preeclampsia included in the meta-analysis [4–22]. For
preeclampsia, thresholds that were most commonly used
were <5th centile (5 studies) and < 10th centile (4 studies).
The most accurate predictor was PAPPA < 0.4 MoM
(multiples of median); LR+ 2.17 (1.48,3.17), LR- 0.91 (0.85,
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Fig. 1 Seletion process: process from initial search to final inclusion for biochemical screening to predict pre-eclampsia/small for gestational
age/preterm delievery
Fig. 2 Study quality: bar chart showing quality of evidence on first trimester biochemical screening markers to predict pre-eclampsia, small for
gestational age and preterm delivery
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0.97), sensitivity 16 % (4 %, 35 %), specificity 93 % (76 %,
99 %), this was a single study. For early preeclampsia, all
the predictive value was calculated from receiver operating
curve analysis. The predictive value for early preeclampsia
(LR+ 2.98 (2.55,3.41), LR-0.70 (0.65, 0.74), sensitivity (39 %
(33 %, 47 %)), specificity (87 % (82 %, 90 %)) was generally
better than that for preeclampsia and late preeclampsia
(LR+ 1.58 (0.86, 2.31), LR-0.87 (0.74, 1.00), sensitivity
29 % (28 %, 30 %), specificity 82 % (81 %, 83 %)).
For SGA there were 19 studies for SGA < 10th centile
and 6 studies for SGA < 5th centile included in the
meta-analysis [4, 6, 7, 10, 11, 23–36] (Fig. 4). The com-
monest threshold used to predict SGA < 10th centile
were PAPPA < 5th centile (9 studies). The best predictor
for SGA <10th centile was PAPPA < 1st centile; LR+ 3.59
(2.77, 4.40), LR- 0.98 (0.97, 0.98), sensitivity 3 % (3 %,
4 %), specificity 99 % (98 %, 99 %). For SGA < 5th centile,
PAPPA < 1st centile was also the most accurate predictor,
Fig. 3 Forest plot for PAPP-A to predict preeclampsia: forest plot showing likelihood ratio of a positive and negative test result with 95 % confidence
intervals (95 % CI) for studies of Pregnancy- Associated Plasma Protein-A (PAPP-A) to predict pre-eclampsia. * continuous: Likelihood ratio calculated
from receiver operating curve analysis
Fig. 4 Forest plot for PAPP-A to predict SGA: forest Plot showing likelihood ratio of a positive and negative test result with 95 % confidence intervals
(95 % CI) for studies of Pregnancy- Associated Plasma Protein-A (PAPP-A) to predict small for gestational age (SGA). * continuous: Likelihood ratio
calculated from receiver operating curve analysis
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LR+ 4.53 (3.40, 6.04), LR-0.97 (0.96, 0.98), sensitivity 4 %
(2 %, 5 %), specificity 99 % (98 %, 100 %).
For preterm delivery there were 12 studies for preterm de-
livery and 6 studies for preterm delivery < 34 weeks included
in the meta-analysis [4, 7, 10, 11, 23-25, 33, 35, 37–40]
(Fig. 5). The commonest threshold used to predict
preterm delivery were <5th centile (6 studies). The best
predictor for preterm delivery was calculated from re-
ceiver operating curve analysis; LR+ 2.99 (1.95, 4.03),
LR- 0.66 (0.60, 0.77), sensitivity 44 % (28 %, 58 %), spe-
cificity 85 % (70 %, 93 %). For preterm delivery < 34 weeks,
PAPPA < 0.3 MoM was the most accurate predictor,
LR+ 3.64 (1.89, 7.02), LR-0.96 (0.93, 1.00), sensitivity 5 %
(1 %, 14 %), specifcity 99 % (93 %, 100 %).
Plancenta protein 13 (PP13)
The results for PP13 are summarized in Fig. 6, all the
predictive value was calculated from receiver operating
curve analysis. The total number of women in these
studies is 60,786. For early preeclampsia there were 6 in-
cluded studies [8, 12, 15, 41-44]. PP13 turns out to be
more accurate predictor for early preclampsia; LR+ 4.20
(3.69, 4.71), LR-0.60 (0.53, 0.66), sensitivity 47 % (39 %,
54 %), specificity 89 % (85 %, 91 %). For preeclampsia
there were 4 studies[8, 21, 45, 46]; LR+ 2.69 (2.05, 3.32),
LR- 0.51 (0.42, 0.59), sensitivity 60 % (50 %, 73 %), speci-
ficity 78 % (64 %, 85 %). For SGA <10th there was only
one included study[29], LR+ 3.70 (3.39, 4.03), LR- 0.70
(0.67, 0.73), sensitivity 36 % (33 %, 41 %), specificity
90 % (88 %, 92 %). For preterm delivery, there were 2 in-
cluded studies [39, 45]; LR+ 4.16 (2.72, 5.61), LR- 0.56
(0.45, 0.67), sensitivity 51 % (37 %, 66 %), specificity
88 % (76 %, 93 %).
Placental growth factor (PlGF)
The results for PlGF are summarized in Fig. 7. There
were 16 included studies. The total number of women in
these studies is 84,424. For preeclampsia there were 2
studies [13, 20]; LR + 4.01(3.74, 4.28), LR-0.67 (0.64,
0.69), sensitivity 40 % (37 %, 43 %), specificity 90 %
(88 %, 91 %). PlGF was also shown to be more predictive
for early preeclampsia[12-14, 17, 19, 20]; LR + 6.05 (5.55,
6.55), LR- 0.48 (0.43, 0.52), sensitivity 56 % (52 %, 61 %),
specificity 91 % (89 %, 92 %). For SGA there were 2 in-
cluded studies [29, 32]; LR+ 2.65 (2.09, 3.20), LR-0.81
(0.77, 0.85), sensitivity 27 % (20 %, 36 %), specificity
90 % (83 %, 94 %).
Human chorionic gonadotrophin (hCG)
The results for hCG to predict preeclampsia are summa-
rized in Fig. 8. The total number of women in these
studies is 112,400. There were 4 included studies in the
meta-analysis [7, 10, 11, 18], and there was single study
for every threshold. The most accurate predictor was
hCG < 0.6MoM; LR+ 1.41 (1.10, 1.82), LR- 0.90 (0.82,
0.99), sensitivity 28 % (2 %, 71 %), specificity 80 % (36 %,
99 %). There were 2 studies and 1 study looking at early
preeclampsia [18, 19] and late preeclampsia [19] respect-
ively as the outcome, results showed no improvement in
prediction.
For SGA < 10th centile there were 9 included studies in
the meta-analysis [7, 11, 23–25, 29, 30, 35, 36] (Fig. 9).
Fig. 5 Forest plot for PAPP-A to predict preterm delivery: forest Plot showing likelihood ratio of a positive and negative test result with 95 %
confidence intervals (95 % CI) for studies of Pregnancy- Associated Plasma Protein-A (PAPP-A) to predict preterm delivery. * continuous: Likelihood
ratio calculated from receiver operating curve analysis
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The commonest thresholds used were hCG < 5th (3
studies) and calculated from receiver operating curve
analysis. The most accurate predictor for SGA < 10th
centile was calculated from receiver operating curve
analysis; LR+ 3.44 (3.26, 3.63), LR-0.73 (0.71, 0.74), sen-
sitivity 34 % (32 %, 37 %), specificity 90 % (89 %, 91 %).
For SGA < 5th centile there were only 2 thresholds stud-
ied with single study for each[7, 10], hCG < 10th centile
was more accurate; LR+ 2.86 (1.97, 4.16), LR-0.90 (0.85,
0.96), sensitivity 15 % (5 %, 26 %), specificity 95 % (87 %,
100 %).
There were 6 studies for preterm delivery [7, 10, 11,
23, 35, 40] and 4 studies for preterm delivery < 34 weeks
[7, 23, 25, 40] included in the meta-analysis (Fig. 10).
The commonest threshold used to predict preterm deliv-
ery were hCG < 5th centile (6 studies). The best predictor
for preterm delivery was hCG < 0.5 MoM; LR+ 2.71
(1.88, 3.54), LR- 0.92 (0.89, 0.96), sensitivity 12 % (5 %,
21 %), specificity 96 % (89 %, 98 %). For preterm delivery
< 34 weeks, hCG > 95th was the most accurate predictor,
LR+ 1.74 (1.22, 2.47), LR-0.96 (0.93, 0.99), sensitivity 9 %
(2 %, 29 %), specificity 95 % (76 %, 99 %).
Discussion
We evaluated the accuracy of five serum screening
markers commonly used in first trimester screening for
preeclampsia, SGA and preterm delivery. The results
showed low predictive accuracy overall. For preeclamp-
sia, the best predictor was PlGF. However, it is im-
portant to point out that this threshold was determined
from a receiver operating characteristic curve and based
only 2 studies. For early and late preeclampsia, the best
predictor was also PlGF. Generally, the predictive value
of serum markers for early preeclampsia is better than
that of late preeclampsia. For SGA the best predictor
overall was PP13 while PAPPA < 1st centile was the best
predictor of SGA < 5th centile. These results were both
based on single studies. For preterm delivery, the best
Fig. 6 Forest plot for PP13 to predict preeclampsia, SGA and preterm delivery: forest Plot showing likelihood ratio of a positive and negative test
result with 95 % confidence intervals (95 % CI) for studies of Placental Protein 13 (PP13) to predict preeclampsia, small for gestational age (SGA)
and preterm delivery. * continuous: Likelihood ratio calculated from receiver operating curve analysis
Fig. 7 Forest plot for PlGF to predict preeclampsia, SGA and preterm delivery: forest Plot showing likelihood ratio of a positive and negative test
result with 95 % confidence intervals (95 % CI) for studies of Placental Growth Factor (PlGF) to predict preeclampsia, small for gestational age
(SGA) and preterm delivery. * continous: Likelihood ratio calculated from receiver operating curve analysis
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predictor was PP13 while PAPPA < 0.3 MoM was the
best predictor of preterm delivery < 34 weeks.
The predict value of first trimester analytes is not worse
compare to that of the second trimester markers. Previous
studies show in the second trimester, the most accurate
predictor of hCG for preeclampsia was hCG > 2.0 MoM,
with LR+ 2.45 (1.57, 3.84), LR- 0.89 (0.83, 0.96); for SGA
was hCG > 2.0 MoM, with LR+ 1.74 (1.48, 2.04), LR-0.95
(0.93, 0.96). The most accurate predictor of PAPPA for
preeclampsia was PAPP-A < 5th centile, with LR + 2.10
(1.57, 2.81), LR- 0.95 (0.93, 0.98); for SGA was PAPP-A < 1st
centile; LR+ 3.50 (2.53, 4.82), LR- 0.98 (0.97, 0.99). On the
other hand, our meta-analysis shows the most accurate
predictor of hCG for preeclampsia was hCG < 0.6 MoM;
LR+ 1.41 (1.10, 1.82), LR- 0.90 (0.82, 0.99), for SGA
was calculated from receiver operating curve analysis;
LR+ 3.44 (3.26, 3.63), LR-0.73 (0.71, 0.74). The most
accurate predictor of PAPPA for preeclampsia was
PAPPA < 0.4 MoM; LR+ 2.17 (1.48, 3.17), LR- 0.91 (0.85,
0.97), for SGA was PAPPA < 1st centile; LR+ 3.59 (2.77,
4.40), LR- 0.98 (0.97, 0.98). A possible explanation for the
apparent difference of hCG change between first trimester
and second trimester is that the low levels at first trimester
are the consequence of impaired placentation and smaller
placental mass, whereas the high levels in the second
trimester may be the result of ‘leakage’ or hypoperfusion-
related stimulation of production of this hormone [47]. Al-
though the symptoms of preeclampsia and FGR generally
Fig. 8 Forest plot for hCG to predict preeclampsia: forest Plot showing likelihood ratio of a positive and negative test result with 95 % confidence
intervals (95 % CI) for studies of Human chorionic gonadotrophin (hCG) to predict preeclampsia. * continuous: Likelihood ratio calculated from
receiver operating curve analysis
Fig. 9 Forest plot for hCG to predict SGA: forest Plot showing likelihood ratio of a positive and negative test result with 95 % confidence intervals
(95 % CI) for studies of Human chorionic gonadotrophin (hCG) to predict small for gestational age (SGA). * continuous: Likelihood ratio calculated
from receiver operating curve analysis
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manifest in the second to third trimester of pregnancy,
their underlying pathology takes place in the first trimester.
One possible reason why preventive strategies have proven
very disappointing at present is that the proposed interven-
tions have commenced in the mid to late second trimester,
when the underlying placental dysfunction may already be
established. Earlier assessment before the establishment of
placental dysfunction may have the potential to improve
predictive value for clinical practice. With the increased
use of first-trimester screening for Down syndrome, there
is the opportunity to ‘piggy back’ screening tests for pre-
eclampsia, FGR and preterm delivery onto existing tests.
As preeclampsia and SGA are diseases with relatively
low prevalence, a clinically useful test would need to have
a high positive LR (> 10) and low negative LR (< 0.10)
[48]. From the results of this review it is unlikely that any
first trimester serum screening marker in isolation will
provide this. Future research should thus concentrate in
two areas. The first is to improve the knowledge of the
biological mechanisms for the abnormal clinical tests by
focusing on the exact placental pathology resulting in the
changes seen in preeclampsia, FGR and preterm delivery.
Preliminary findings suggest that genomic studies can im-
prove our understanding of the early pathophysiology of
preeclampsia/FGR/preterm delivery at the molecular level.
It is hoped that proteomics, metabolomics, and other
techniques will allow us to provide potential targets for
the development of biomarkers with high enough pre-
dictive and prognostic information to be translated into
clinical practice. Secondly, future research should attempt
to improve the predictive value by combining Doppler
sonography, different maternal serum analytes and clinical
characteristics. The use of multiple parameters increases
the specificity and sensitivity of the screening possibly
because they reflect different pathways to the disease
process, with abnormal Doppler reflecting the inadequate
trophoblastic invasion of the maternal spiral arteries and
abnormal biomarkers demonstrating the dysregulated
secretory activity by the trophoblasts. However, some
studies showed no additive effect of combining different
markers, likely secondary to correlation between the
markers (such as ADAM12 and PAPP-A, sFlt-1 and sEng)
[47]. Sequential measurements of markers might also
improve the risk assessment as individual changes from
the first to second trimesters have been shown to occur in
preeclampsia and FGR.
Our result also showed the detection rate of first tri-
mester serum markers for early preeclampsia is better
than that for late preeclampsia. This disparity may result
from different etiologies between early and late pre-
eclampsia. Early preeclampsia is said to be associated
with inadequate and incomplete trophoblast invasion of
maternal spiral arteries, and is often complicated with a
fetal growth restriction. In contrast, the late onset type
of preeclampsia is often related to enlarged placental
mass or surface (diabetes, multiple pregnancies, anemia,
high altitude). It often shows normal or only slightly al-
tered behavior of the uterine spiral arteries and thus no
changes in the blood flow of the umbilical arteries. Fetus
with late onset preeclampsia often shows no signs of any
growth restriction [49]. Since abnormal concentration of
serum markers in the first trimester is caused by intrin-
sic alteration of the villous trophoblast, it is reasonable
that predictive value would be poorer for late onset pre-
eclampsia with normal or only slightly altered tropho-
blast invasion in the first trimester.
The strength of the study includes generally sufficient
quality and a quality assessment of studies based on rec-
ognized criteria. However, there are still some limita-
tions. First, there is large discordance in reports of cutoff
Fig. 10 Forest plot for hCG to predict prelivery: forest Plot showing likelihood ratio of a positive and negative test result with 95 % confidence
intervals (95 % CI) for studies of Human chorionic gonadotrophin (hCG) to predict preterm delivery
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points, thus, a formal meta-analysis with estimated over-
all relative risks was not feasible. Secondly, the number
of studies for some cutoffpoints is so small that they lead
to some contradictive results. For example, our analysis
shows the best predictor for preterm delivery was
hCG < 0.5 MoM while the best predictor for preterm
delvery < 34 weeks is a hCG > 95th centile. This odd re-
sult is probably due to the small numbers of studies
since there is only one study for each threshold. Clearly
large scale studies are needed for more reliable evalu-
ation. Thirdly, all of the studies we selected are popula-
tion of low risk so we are unable to perform a sub
analysis. We didn’t choose the population of high risk
since there are few studies on it. More studies are
needed to analyse predictive accuracy by the type of
population.
Conclusion
First trimester screening analytes have low predictive
accuracy for pre-eclampsia, SGA and preterm delivery.
However, the predict value of first trimester analytes is not
worse compare to that of the second trimester markers.
They may be useful in prediction when combined with
other tests. Early pathophysiology of preeclampsia/FGR/
preterm delivery should be studied to develop biomarkers
with high enough predictive and prognostic information
to be translated into clinical practice.
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